Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.

Date publication

mai 2023

Journal

JHEP reports : innovation in hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
Seidensticker M, Öcal O, Schütte K, Malfertheiner P, Berg T, Loewe C, Klümpen HJ, van Delden O, Ümütlü MR, Ben Khaled N, de Toni EN, Seidensticker R, Aghdassi A, Tran A, Bronowicki JP, Peynircioglu B, Sangro B, Pech M, Ricke J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36968218

Résumé

The aim of the study was to evaluate the efficacy and safety of adjuvant sorafenib treatment compared with placebo in patients with hepatocellular carcinoma who underwent local ablation.

Mots clés

Adjuvant, BCLC, Barcelona Clinic Liver Cancer, CONSORT, Consolidated Standards of Reporting Trials, CT, computed tomography, ECOG PS, Eastern Cooperative Oncology Group Performance Status, HCC, hepatocellular carcinoma, HR, hazard ratio, Hepatocellular carcinoma, ITT, intention-to-treat, Local ablation, MRI, magnetic resonance imaging, MWA, microwave ablation, PP, per protocol, RFA, radiofrequency ablation, RFS, relapse-free survival, SIRT, selective internal radiation therapy, SORAMIC, SORAfenib in combination with local MICro-therapy guided by gadolinium-EOB-DTPA-enhanced MRI, Sorafenib, TTR, time-to-recurrence, Time-to-recurrence

Référence

JHEP Rep. 2023 05;5(5):100699